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Abstract 
Objective: The purpose of my study was to determine the relationship of Type 2  diabetes mellitus in women with 
PCOS. Background: PCOS is a hormonal disorder affecting millions of women around the world. 1 in every 10 
women have PCOS but many women go years before receiving the diagnosis. In fact it is estimated that 70% of 
PCOS cases have a root cause is insulin resistance, A major risk factor for Type 2 diabetes mellitus. More than 
half of women with PCOS develop type 2 diabetes. PCOS is linked with higher levels of circulating insulin, which 
is characteristic in type 2 diabetes. IR is the typical condition of subjects with T2D. Women with PCOS share with 
people with T2D the same impaired glucose pattern consisting of a prevalent disturbance of fasting blood glucose. 
Higher levels of IR stress the pancreatic beta cell function, resulting in earlier functional depletion of insulin 
secretion capacity and higher risk of developing T2D. In this Systematic review I wanted to determine the 
incidence of type 2 diabetes in women with PCOS. According to the studies that I reviewed women with PCOS 
have a markedly increased risk of developing type 2 diabetes then women without PCOS and there is a higher 
prevalence of PCOS in those women who have Type 2 diabetes mellitus rather than non-diabetic. Method:An 
electric database search was performed (google scholar, PubMed and science direct)  without time limit until 
january 2020. All studies, fully available in English, assessing the incidence Type II Diabetes Mellitus in Women 
with PCOS.  Study design: Systematic review.  Results:I reviewed 22 articles and found that there were high risk 
of Diabetes Mellitus Type 2 in PCOS females then other one. Middle aged women with PCOS were having 
elevated risk of Type 2 Diabetes Mellitus, So therefore it propped up the needs of PCOS for routine screening of 
diabetes. The information or data from articles likewise gave furthur clinical bits of knowledge on the side of 
focusing on BMI (Body Mass Index), glucose (fasting glucose and after glucose ingestion) and in risk stratification 
and intervention for glucose homeostasis maintenance.  
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Introduction 
Polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus are both common conditions associated with 
insulin resistance and compensatory hyper insulinaemia.  Polycystic ovary syndrome (PCOS) has, since its first 
description by Stein and Leventhal in 1935, become one of the commonest disorders in women, affecting 5 to 10% 
in the reproductive age-group1. This common medical condition has brought gynecologists, endocrinologists, 
cardiologists, pediatricians, and dermatologists together2.The disorder manifests as obesity, hirsutism, menstrual 
disturbances, acne vulgaris, male-pattern baldness, recurrent abortions, infertility, an-ovulation, and psychological 
and psychosexual morbidity3.It is an important cause of hirsutism and of infertility in our population4. With the 
advances and refinement in ultrasound technology, the presence of polycystic appearance of ovaries has 
increasingly been accepted as an essential part of the diagnosis of this syndrome and ultrasound suggestion of PCO 
has recently been introduced as one of the three diagnostic criteria of PCOS in Rotterdam consensus workshop 
20035.Using the most conservative criteria for transabdominal studies, such as presence of ≥ 10 peripheral cysts 
per ovary, each 2–8 mm, and thickened stroma, some authors have shown that as many as 21–23% of normal 
female population have PCO on ultrasound6.Some women with otherwise confirmed PCOS may have normal sized 
ovaries on ultrasound and normal sized ovaries without increased folicllarity don't preclude the diagnosis in proper 
clinical settings7.The pathophysiology of PCOS, one of the commonest endocrinopathies, is far from clear. A 
plethora of data point to insulin resistance (IR) and hyperinsulinemia as the central factor, a suggestion supported 
by clinical benefits of insulin sensitizers8. T2DM, which accounts for 90–95% of all diabetes mellitus, is a common 
metabolic disorder, characterized by a combination of IR and insulin secretory defects, occurring in varying 
proportions9. Both T2DM and PCOS are now considered to be two metabolically similar but phenotypically 
different expressions of the same syndromic continuum with IR being the common and pivotal link, which may 
be genetically determined10. Women with PCOS are also at increased risk for cardiovascular disease (CVD), given 
the high prevalence of the metabolic syndrome among them11. Many studies have revealed an increased prevalence 
of various abnormalities of glucose tolerance in women with PCOS. Polycystic ovary syndrome (PCOS) is the 
most frequent endocrine condition in women, but the diagnosis of PCOS is only possible during premenopausal 
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years. The Rotterdam Criteria are used to establish the diagnosis of PCOS when other causes of the clinical 
phenotype are excluded. PCOS is characterized by insulin resistance and hyperinsulinemia and insulin resistance 
is closely associated with obesity in PCOS. The new guidelines for the management of women with PCOS, 
published in 2018, recommend that glycemic status should be assessed at time of diagnosis and thereafter every 
1–3 years, depending on the considered risk, for early detection of IGT and/or T2DM12. It is important to study if 
development of T2DM can be predicted. 
 
Discussion 
According to the Office on Women’s Health, around half of those women with PCOS develop either diabetes or 
prediabetes before the age of 40. 
Research from 2017 by Katrine Hass Rubin suggests that people with PCOS are four times more likely to 
develop type 2 diabetes than similar peers without the disorder  and that diabetes is diagnosed four years earlier in 
women with PCOS compared to controls13. 
A study by A. E. Joham: Around 8,000 females found that those with PCOS had a much higher risk of 
developing gestational or type 2 diabetes. The researchers note that this finding was independent of body mass14. 
According to a review from 2016, various other studies have found a link between type 2 diabetes and PCOS. 
In 2005 A prospective study by Abdul H.Zargar was done and objective of this srudy was Prevlence of 
Ultrasonography proved polycystic ovaries in North women with T2DM. One hundred and five reproductive age 
group women with diet and /or oral hypoglycemic treated T2DM were done. Sixty age-matched non-diabetic 
women served as controls. Ultrasonographic prevalence of PCO was higher in women with diabetes than in non-
diabetic subjects (61.0% vs. 36.7%, P < 0.003) whereas that of PCOS was 37.1% in diabetic subjects and 25% in 
non-diabetic controls (P > 0.1). Diabetic women with PCO had diabetes of significantly longer duration than those 
without PCO (4.19±2.0 versus 2.9±1.6 yrs; p < 0.05). This study demonstrates a higher prevalence of PCO in 
women with T2DM as compared to non-diabetic subjects15. 
In 2001 Jenifer J.conn published a case on cross sectional study and objective of  this study was The 
prevalence of polycystic ovaries in women with type 2 diabetes mellitus. 49 women were presented of whom 38 
(76%) patients agreed to be studied. Eighty‐two percent of women with type 2 diabetes mellitus had polycystic 
ovaries on ultrasound. Of these women, 52% had clinical evidence of cutaneous hyperandrogenism and/or 
menstrual disturbance.Women with type 2 diabetes mellitus have a higher prevalence of polycystic ovaries than 
that reported in the general population. Not all women with hyperinsulinaemia due to type 2 diabetes mellitus, 
however, develop PCO suggesting that hyper insulinaemia alone is not sufficient for the expression of this ovarian 
morphology16.  
In 2002, Review of published literature was done by Ovalle F and the objective of this study was to review 
the definition and prevalence of two insulin resistance (IR)-associated phenotypes, polycystic ovary syndrome 
(PCOS) and type 2 diabetes mellitus, as well as the risk and nature of their simultaneous presentation. Insulin 
resistance affects between 10% and 25% of the general population. Two common disorders frequently associated 
with IR are PCOS, affecting 4% to 6% of reproductive-aged women, and type 2 diabetes mellitus, which is 
observed in about 2% to 6% of similarly aged women. Overall, about 50% to 70% of women with PCOS and 80% 
to 100% of patients with type 2 diabetes mellitus have variable degrees of IR. Insulin resistance and its secondary 
hyperinsulinemia appear to underlie many of the endocrine features of PCOS in a large proportion of such patients. 
The risk of type 2 diabetes mellitus among PCOS patients is 5- to 10-fold higher than normal. In turn, the risk of 
PCOS among reproductive-aged type 2 diabetes mellitus patients appears to be similarly increased. It remains to 
be determined whether PCOS and type 2 diabetes mellitus represent no more than different clinical manifestations 
of the same IR syndrome, with their phenotypic differences due to the presence or absence of a coincidental genetic 
defect at the level of the ovary or pancreas, respectively, or representing the result of etiologically different 
subtypes of IR syndromes17. 
In 2006, Monique Y done a study and objective of his study was know the Risk of T2DM and impaired fasting 
glucose among pcos subjects. follow-up of 8 years and Women with polycystic ovary syndrome (PCOS) often 
develop type 2 diabetes mellitus (T2DM). To determine the magnitude of risk of developing T2DM among women 
with PCOS, development of T2DM was prospectively assessed among women who had T2DM (n = 97) and 
controls (n = 95) using Kaplan-Meier survival analysis and Cox proportional hazards modeling. The women with 
T2DM had higher baseline weight (body mass index, P < 0.01) and lower insulin sensitivity (homeostasis 
assessment model of insulin resistance, P < 0.01). The 8-year incidence rate among cases and controls was 13.4% 
and 5.8%, respectively (relative risk = 2.3). Obese cases had a fivefold risk of T2DM developing (P < 0.01) 
compared with age-adjusted obese controls, indicating significant interaction between PCOS and obesity to effect 
T2DM risk18.  
Heather R. Peppard done a study and objective of this study was to determine the prevalence of PCOS among 
women with type 2 diabetes, He conducted a retrospective cross-sectional prevalence study. He reviewed the 
medical records of all women seen in the Diabetes Clinic of the Medical College of Virginia Hospitals between 
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January 1995 through February 2000. 618 women with diabetes and identified 47 women eligible for study. Of 
the 47 women, 30 consented to an evaluation. Of the 30 women evaluated, 8 were identified as having PCOS 
resulting in a prevalence of 26.7%. He concluded that PCOS occurs frequently among women with type 2 
diabetes19. 
Panicha Chantrapanichkul in July 2019, done a retrospective cohort study and objective of his study was to 
investigate the prevalence of type 2 diabetes mellitus (T2DM) at the 5-year follow-up after polycystic ovarian 
syndrome (PCOS) diagnosis compared between lean and overweight/obese groups. This retrospective cohort study 
included who 400 prediabetes PCOS women. Participants were divided into either the lean group (body mass index 
[BMI]: < 23 kg/m2) or the overweight/obese group (BMI: ≥ 23 kg/m2). Patient demographic, clinical 
characteristics, metabolic profiles, and laboratory values were collected and compared between groups at baseline 
and during follow-up for 5 years.At the end of the follow-up, overweight/obese group had a higher risk for 
developing T2DM than lean group (11.5% vs. 0.5%, p < 0.001). The factors found to be independently associated 
with increased risk for developing T2DM were BMI ≥ 23 kg/m2 (odds ratio [OR]: 1.075, p = 0.047). 
Overweight/obese PCOS patients were found to be at significantly higher risk for developing T2DM than lean 
PCOS patients.20. 
S Weerakiet in march 2001 done a case study, To determine the prevalence of abnormalities of glucose 
metabolism in Asian women with polycystic ovary syndrome (PCOS) and to assess the different impacts of the 
1985 and 1999 WHO consultations and the ADA criteria for the diagnosis of type 2 diabetes mellitus (DM). 
Eighty-five women with PCOS were consecutively included in the study at the Reproductive Endocrinology Unit, 
Department of Ob-Gyn, Ramathibodi Hospital, Mahidol University. All women underwent a standard oral glucose 
tolerance test (OGTT). Fasting insulin and testosterone levels were also measured. Seventy-nine women consented 
to the OGTT. The prevalence of impaired glucose tolerance (IGT) and type 2 DM was 22.8 and 15.2% with the 
1985 WHO criteria, and 20.3 and 17.7% according to the 1999 WHO consultation criteria, respectively. The 
recommendation of the ADA using the fasting glucose levels could only determine a prevalence of 6.3% for type 
2 DM. The fasting insulin and testosterone levels were significantly higher in DM than IGT and normal glucose 
tolerance (NGT) subgroups. The PCOS women with abnormalities of glucose metabolism had a greater body mass 
index (BMI), higher fasting glucose and 2-h post-load glucose levels than those with NGT. The prevalence of 
glucose intolerance significantly increased with BMI. Similar to other ethnic populations, Asian women with 
PCOS are at risk of developing IGT and type 2 DM especially if obese. The recommendation of the ADA is not 
appropriate for the diagnosis of type 2 DM in PCOS women21 
The study was conducted by Massoud Amini to investigate the prevalence of PCOS in type 2 diabetic 
patients. Type 2 diabetic women (n = 157) of reproductive age were by a convenience sampling method. PCOS 
was confirmed using the clinical diagnosis criteria.The diabetic patients were divided into two groups according 
to the presence of PCOS. Baseline demographic characteristics were obtained by questionnaire, and body weight, 
height, waist circumference, blood pressure and some biochemical indices were measured in both groups.The 
prevalence of PCOS was high (8.3%, 95% confidence interval 4.5–13.4%) in these type 2 diabetic women. The 
onset of diabetes occurred at a lower age in the PCOS group, who also displayed significantly greater waist 
circumference and body mass index (p<0.05). No difference in lipid profile, glycosylated hemoglobin or blood 
pressure was observed between the two group. PCOS is highly prevalent in type 2 diabetic patients. Hence, 
focusing the treatment on insulin sensitizers in these patients should improve both the metabolic and non-metabolic 
complications of PCOS.22 
 
Conclusion 
It is obvious from the systematic review  that the ladies which are obese has a high danger of developing diabetes 
mellitus type 2 and there is a higher predominance of pcos in those ladies who have type 2 diabetes mellitus instead 
of non-diabetic and women with pcos have a markedly high danger of developing  type 2 diabetes (multiple times 
more) at that point ladies without pcos.the hazard of type 2 diabetes is especially raised in ladies with pcos in 
middle-age and accordingly builds up the requirement for routine screening of pcos for diabetes over time.PCOS 
is related with a two times increased risk for type 2 diabetes (t2d) 
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